Table 1.
| Demographic and clinical characteristics | SCZ (n = 20) | HC (n = 24) | Test statistic | P value |
|---|---|---|---|---|
| Age: mean (SD) | 41.50 (6.76) | 40.50 (7.58) | t(42) = −0.46 | 0.65 |
| Gender/male: n (%) | 17 (85) | 21 (87.5) | FET | |
| WASI (IQ): mean (SD) | 97.20 (16.69) | 110.29 (14.11) | t(41) = 2.82 | < 0.01 |
| PANSS Positive: mean (SD) | 19 (4.7) | -- | -- | -- |
| PANSS Negative: mean (SD) | 20.50 (4.95) | -- | -- | -- |
| PANSS General: mean (SD) | 38.45 (7.99) | -- | -- | -- |
| PANSS Total: mean (SD) | 78.21 (14.5) | -- | -- | -- |
| Medication: mean (SD)a | 562.90 (422.1) | -- | -- | -- |
SCZ: volunteers diagnosed with schizophrenia, HC: healthy controls, SD: standard deviation, WASI: Wechsler Abbreviated Scale of Intelligence, PANSS: Positive and Negative Syndrome Scale, FET: Fisher’s Exact Test.
a
Chlorpromazine equivalent (mg per day) – all volunteers were on stable atypical medication.